Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFR
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFR
Authors
Keywords
-
Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 42, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-11-04
DOI
10.1186/s13046-023-02866-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter study
- (2023) Hyunwook Kim et al. LUNG CANCER
- A dual-action niclosamide-based prodrug that targets cancer stem cells and inhibits TNBC metastasis
- (2023) Ji Hyeon Kim et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial
- (2023) Byoung Chul Cho et al. NATURE MEDICINE
- Emerging Roles of Aldehyde Dehydrogenase Isoforms in Anti-cancer Therapy Resistance
- (2022) Michele Zanoni et al. Frontiers in Medicine
- A synchronized dual drug delivery molecule targeting cancer stem cells in tumor heterogeneity and metastasis
- (2022) Ji Hyeon Kim et al. BIOMATERIALS
- Role of ABCB1 in mediating chemoresistance of triple-negative breast cancers
- (2021) Yomna S. Abd El-Aziz et al. BIOSCIENCE REPORTS
- HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence
- (2021) Jianjiang Fu et al. ONCOGENE
- MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer
- (2021) Byoung Chul Cho et al. Future Oncology
- Repurposing Tyrosine Kinase Inhibitors to Overcome Multidrug Resistance in Cancer: A Focus on Transporters and Lysosomal Sequestration
- (2020) Maria Krchniakova et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-cMet Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC
- (2020) Jiyeon Yun et al. Cancer Discovery
- Repurposing of α1-Adrenoceptor Antagonists: Impact in Renal Cancer
- (2020) Meredith Mihalopoulos et al. Cancers
- STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review
- (2019) Jiang-Jiang Qin et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Cancer stem cells and their unique role in metastatic spread
- (2019) Teresa Bernadette Steinbichler et al. SEMINARS IN CANCER BIOLOGY
- Intraperitoneal Route of Drug Administration: Should it Be Used in Experimental Animal Studies?
- (2019) Abdullah Al Shoyaib et al. PHARMACEUTICAL RESEARCH
- STAT3, stem cells, cancer stem cells and p63
- (2018) Michaela Galoczova et al. CELLULAR & MOLECULAR BIOLOGY LETTERS
- The biology and role of CD44 in cancer progression: therapeutic implications
- (2018) Chen Chen et al. Journal of Hematology & Oncology
- Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer
- (2016) Xiaoxian Li et al. BREAST CANCER RESEARCH AND TREATMENT
- CD44 correlates with clinicopathological characteristics and is upregulated by EGFR in breast cancer
- (2016) Hanxiao Xu et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
- (2016) Giampaolo Bianchini et al. Nature Reviews Clinical Oncology
- TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells
- (2016) D-W Wu et al. Cell Death & Disease
- Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers
- (2016) Erik S. Linklater et al. Oncotarget
- Identification of Distinct Breast Cancer Stem Cell Populations Based on Single-Cell Analyses of Functionally Enriched Stem and Progenitor Pools
- (2016) Nina Akrap et al. Stem Cell Reports
- Constitutive activation of STAT3 in breast cancer cells: A review
- (2015) Kasturi Banerjee et al. INTERNATIONAL JOURNAL OF CANCER
- Vimentin contributes to epithelial-mesenchymal transition cancer cell mechanics by mediating cytoskeletal organization and focal adhesion maturation
- (2015) Ching-Yi Liu et al. Oncotarget
- Cancer metastases: challenges and opportunities
- (2015) Xiangming Guan Acta Pharmaceutica Sinica B
- cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?
- (2014) Patricia B Gaule et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Tumor heterogeneity and cancer stem cell paradigm: Updates in concept, controversies and clinical relevance
- (2014) Anup Kumar Singh et al. INTERNATIONAL JOURNAL OF CANCER
- Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma
- (2014) Zhousan Zheng et al. MEDICAL ONCOLOGY
- cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer
- (2014) Joohyuk Sohn et al. Journal of Cancer
- (−)Doxazosin is a necessary component for the hypotensive effect of (±)doxazosin during long-term administration in conscious rats
- (2013) Jing Zhao et al. ACTA PHARMACOLOGICA SINICA
- MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer
- (2013) Yu Jin Kim et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting the EGFR signaling pathway in cancer therapy
- (2012) Parthasarathy Seshacharyulu et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- An overview of the c-MET signaling pathway
- (2011) Shawna Leslie Organ et al. Therapeutic Advances in Medical Oncology
- Characteristics of triple-negative breast cancer
- (2010) Tim C. de Ruijter et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Targeting Breast Cancer Stem Cells
- (2010) Suling Liu et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors
- (2009) Michalis V Karamouzis et al. LANCET ONCOLOGY
- Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer
- (2009) C. R. Graveel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More